Value Stock - Dividend - Research Selection
ISIN: , WKN:
Market price date:
Market price:
Market price:
Fundamental data and company key figures of the share
| Annual reports in | |||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Key figures | |||||||||||||||||||||||||||||||||||||||||||||||||
| Cash flow | |||||||||||||||||||||||||||||||||||||||||||||||||
| Net operating cash flow | |||||||||||||||||||||||||||||||||||||||||||||||||
| Capital Expenditures | |||||||||||||||||||||||||||||||||||||||||||||||||
| Free cash flow | |||||||||||||||||||||||||||||||||||||||||||||||||
| Balance sheet | |||||||||||||||||||||||||||||||||||||||||||||||||
| Total Equity | |||||||||||||||||||||||||||||||||||||||||||||||||
| Liabilities & Shareholders equity | |||||||||||||||||||||||||||||||||||||||||||||||||
| Income statement | |||||||||||||||||||||||||||||||||||||||||||||||||
| Net income | |||||||||||||||||||||||||||||||||||||||||||||||||
| Eps (diluted) | |||||||||||||||||||||||||||||||||||||||||||||||||
| Diluted shares outstanding | |||||||||||||||||||||||||||||||||||||||||||||||||
| Net sales/revenue | |||||||||||||||||||||||||||||||||||||||||||||||||
Do you want to do make a detailed fundamental analysis of this stock?
✓ NEW Fundamental API Access to 500 data points per month
✓ Fundamental data up to 25 years
✓ Comparison to all other stocks by the FScore
✓ Time saving!
✓ NEW Fundamental API Access to 500 data points per month
✓ Fundamental data up to 25 years
✓ Comparison to all other stocks by the FScore
✓ Time saving!
How our site works ...
✓ Non-binding 7 days without automatic subscription
✓ No termination required after the free week
✓ Finanzoo fundamental analysis
✓ Data updated daily
✓ Virtual depots
✓ Share alarms via email
✓ Subscription can be canceled at any time at the end of the month
✓ Choice of desired shares
✓ Over 2000 stock analyzes available
✓ Bitcoin payment possible if you do not want to subscribe
Price for monthly subscription $ 19.99 / month including VAT.
| Description | Data |
|---|---|
| Symbol | |
| Market Capitalization | USD |
| Country | |
| Indices | |
| Sectors | |
| Raw Data Source | |
| Stock Split | |
| Internet |
Description of the company
The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,
NEWS
Viatris completes $3B divestiture of biosimilars business
2022-11-29
Viatris Inc.'s divestiture of its biosimilars business to Biocon was completed Tuesday with a $2 billion cash payment to the Canonsburg pharmaceutical company, the first of an expected $9 billion in divestitures. The terms of the agreement with Biocon Biologics Ltd. also include $1 billion in convertible preferred equity in Biocon Biologics that the companies said amounted to a 12.9% stake in the company plus $335 million in cash in 2024. Viatris (Nasdaq: VTRS) will also provide commercialization and regulatory-related services to Biocon for two years.
Viatris Completes Biosimilars Transaction with Biocon Biologics
2022-11-29
Viatris Inc. (NASDAQ: VTRS) today announced that it has closed its transaction with Biocon Biologics Limited ("Biocon Biologics"), creating what Viatris expects to be a unique fully vertically integrated global biosimilars leader. Viatris and Biocon Biologics have entered a Transition Services Agreement (TSA) pursuant to which Viatris will provide commercialization and certain other transition services for an expected two-year period intended to ensure business continuity for patients, customers
Better Dividend Stock: AbbVie or Viatris?
2022-11-26
AbbVie (NYSE: ABBV) and Viatris (NASDAQ: VTRS) have a lot more in common than first glances would suggest. The two were both spun off from larger companies and now deliver above-average dividend yields. In AbbVie's case, it is the patent cliff next year for its immunology drug Humira, the top-selling drug last year other than COVID-19 vaccines.
Mittleman Global Value Equity Fund Q3 2022 Report
2022-11-23
The Mittleman Global Value Equity Fund (MGVEF) declined 6.5% in Q3 2022, vs. a decline of 0.3% in the MSCI ACW Net Total Return Index. Click here to read the full fund letter.
3 Unstoppable Growth Stocks to Buy and Hold
2022-11-19
Three simple words can make you a lot of money over the long run: buy and hold. Here's why they chose Pfizer (NYSE: PFE), Thermo Fisher Scientific (NYSE: TMO), and Vertex Pharmaceuticals (NASDAQ: VRTX). Prosper Junior Bakiny (Pfizer): Pfizer has grown its top line at an incredible pace over the past two years.
Viatris And Oyster Point: Mylan All Over Again?
2022-11-17
VTRS agreed to acquire OYST and Famy Life Sciences for combined $700 million to $750 million. OYST shareholders receive $11 plus a CVR (potentially worth $1-$2) per share.
Viatris Insider Trading Scheme Busted
2022-11-14
The executive went through elaborate measures to hide his activity
3 Stocks With Dividends of 3% or More to Buy on the Dip
2022-11-14
Fresenius Medical Care (NYSE: FMS), Pfizer (NYSE: PFE), and Viatris (NASDAQ: VTRS) have seen their shares slide so far this year. Fresenius, a German company that specializes in healthcare services for kidney dialysis patients, has seen its shares fall more than 54% this year. Fresenius reported third-quarter numbers on Nov. 1, and the results were mixed.
Tracking Christopher Davis' Davis Selected Advisers 13F Portfolio - Q3 2022 Update
2022-11-14
Davis Selected Advisers 13F portfolio value decreased from $15.59B to $14.06B this quarter. Read more here.
Viatris Insider Trading Scheme - GuruFocus.com
2022-11-14
GuruFocus Article or News written by Praveen Chawla and the topic is about: The executive went through elaborate measures to hide his activity